Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 16/20 | 0.84 |
| ▸ | AKT1 | P31749 | 14/20 | 0.84 |
| ▸ | AURKB | Q96GD4 | 11/20 | 0.84 |
| ▸ | INCENP | Q9NQS7 | 10/20 | 0.84 |
| ▸ | AURKA | O14965 | 4/20 | 0.70 |
| ▸ | AKT2 | P31751 | 1/20 | 0.62 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18537657 | 1.00 | RPS6KB1 (0.84) | RPS6KB1AKT1AURKBINCENPAURKA | |
| SCHEMBL18537626 | 0.91 | RPS6KB1 (1.00) | RPS6KB1AKT1AURKBINCENPAURKA | |
| SCHEMBL8515423 | 0.91 | RPS6KB1 (1.00) | RPS6KB1AKT1AURKBINCENPAURKA | |
| SCHEMBL8588080 | 0.91 | RPS6KB1 (0.87) | RPS6KB1AKT1AURKBINCENPAURKA | |
| SCHEMBL8588086 | 0.91 | RPS6KB1 (0.87) | RPS6KB1AKT1AURKBINCENPAURKA | |
| SCHEMBL8514881 | 0.91 | RPS6KB1 (0.85) | RPS6KB1AKT1AURKBINCENPAURKA | |
| SCHEMBL18537708 | 0.91 | RPS6KB1 (0.85) | RPS6KB1AKT1AURKBINCENPAURKA | |
| SCHEMBL9290661 | 0.89 | RPS6KB1 (1.00) | RPS6KB1AKT1AURKBINCENPAURKA | |
| SCHEMBL18537631 | 0.89 | RPS6KB1 (1.00) | RPS6KB1AKT1AURKBINCENPAURKA | |
| SCHEMBL17865863 | 0.88 | AKT1 (0.66) | RPS6KB1AKT1AURKBINCENPAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643313-B9 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2017-02-22 | — | — | EP | claimed |
| EP-2643313-B1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2016-06-29 | — | — | EP | claimed |
| US-8946247-B2 | Quinazoline carboxamide azetidines | MERCK PATENT GMBH (DE) | 2015-02-03 | — | — | US | claimed |
| EP-2643313-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | Merck Patent GmbH (DE) | 2013-10-02 | — | — | EP | claimed |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | US | claimed |
| WO-2012069146-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2012-05-31 | — | — | WO | claimed |
| EP-2643313-B9 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2643313-B9 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2643313-B1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| EP-2643313-B1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-8946247-B2 | Quinazoline carboxamide azetidines | MERCK PATENT GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946247-B2 | Quinazoline carboxamide azetidines | MERCK PATENT GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946247-B2 | Quinazoline carboxamide azetidines | MERCK PATENT GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| WO-2012069146-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | AZI2, NQO2, ABL1 | RPS6KB1 1965/4885AKT1 3082/4885AURKB 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.